World Journal of *Gastroenterology*

World J Gastroenterol 2017 April 14; 23(14): 2453-2634





Published by Baishideng Publishing Group Inc

J G World Journal of Gastroenterology

Contents

Weekly Volume 23 Number 14 April 14, 2017

EDITORIAL

2453 Noninvasive molecular analysis of *Helicobacter pylori*: Is it time for tailored first-line therapy? Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A

REVIEW

- 2459 Pathogenesis and clinical spectrum of primary sclerosing cholangitis Gidwaney NG, Pawa S, Das KM
- 2470 Biliary tract cancer stem cells - translational options and challenges Mayr C, Ocker M, Ritter M, Pichler M, Neureiter D, Kiesslich T

MINIREVIEWS

- 2483 Potential role of nutraceutical compounds in inflammatory bowel disease Larussa T, Imeneo M, Luzza F
- Unusual gastric tumors and tumor-like lesions: Radiological with pathological correlation and literature review 2493 Lin YM, Chiu NC, Li AFY, Liu CA, Chou YH, Chiou YY
- 2505 New progress in roles of nitric oxide during hepatic ischemia reperfusion injury Zhang YQ, Ding N, Zeng YF, Xiang YY, Yang MW, Hong FF, Yang SL

ORIGINAL ARTICLE

Basic Study

2511 Berberine displays antitumor activity in esophageal cancer cells in vitro Jiang SX, Qi B, Yao WJ, Gu CW, Wei XF, Zhao Y, Liu YZ, Zhao BS

Case Control Study

- 2519 Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer Inaoka K, Kanda M, Uda H, Tanaka Y, Tanaka C, Kobayashi D, Takami H, Iwata N, Hayashi M, Niwa Y, Yamada S, Fujii T, Sugimoto H, Murotani K, Fujiwara M, Kodera Y
- 2527 Colors of vegetables and fruits and the risks of colorectal cancer Lee J, Shin A, Oh JH, Kim J



Contents

Retrospective Cohort Study

- 2539 Impact of vitamin D on the hospitalization rate of Crohn's disease patients seen at a tertiary care center Venkata KVR, Arora SS, Xie FL, Malik TA
- 2545 Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort

Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M

Retrospective Study

- 2556 Laparoscopic approach to suspected T1 and T2 gallbladder carcinoma Ome Y, Hashida K, Yokota M, Nagahisa Y, Okabe M, Kawamoto K
- 2566 Clinical characteristics of peptic ulcer perforation in Korea Yang YJ, Bang CS, Shin SP, Park TY, Suk KT, Baik GH, Kim DJ
- 2575 Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer Zhang JL, Liu M, Yang Q, Lin SY, Shan HB, Wang HY, Xu GL

Clinical Trials Study

- 2585 *PIK3CA* gene mutations in Northwest Chinese esophageal squamous cell carcinoma *Liu SY, Chen W, Chughtai EA, Qiao Z, Jiang JT, Li SM, Zhang W, Zhang J*
- 2592 Endothelial progenitor cells in peripheral blood may serve as a biological marker to predict severe acute pancreatitis

Ha XQ, Song YJ, Zhao HB, Ta WW, Gao HW, Feng QS, Dong JZ, Deng ZY, Fan HY, Peng JH, Yang ZH, Zhao Y

2601 Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder *Wu ZC, Xiong L, Wang LX, Miao XY, Liu ZR, Li DQ, Zou Q, Liu KJ, Zhao H, Yang ZL*

Observational Study

- 2613 Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis KuklaM, Waluga M, Żorniak M, Berdowska A, Wosiewicz P, Sawczyn T, Bułdak RJ, Ochman M, Ziora K, Krzemiński T, Hartleb M
- 2625 Upper gastrointestinal cancer burden in Hebei Province, China: A population-based study *Li DJ, Liang D, Song GH, Li YW, Wen DG, Jin J, He YT*



Contents		Volui	<i>World Journal of Gastroenterology</i> ne 23 Number 14 April 14, 2017		
ABOUT COVER		Editorial board member of <i>World Journal of Gastroenterology</i> , Vicente Lorenzo- Zuniga, MD, PhD, Associate Professor, Chief Doctor, Staff Physician, Endoscopy Unit, Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol/CIBERehd, Badalona 08916, Spain			
AIMS AND SCOPE		World Journal of Gastroenterology (World J Gastroenterol, WJG, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. WJG was established on October 1, 1995. It is published weekly on the 7 th , 14 th , 21 st , and 28 th each month. The WJG Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries. The primary task of WJG is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. WJG is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.			
NDEXING/ABSTRACTING <i>World Journal of Gastroenterology (WJG)</i> is now indexed in Current Contents [®] /Clinical Science Citation Index Expanded (also known as SciSearch [®]), Journal Citation Report Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Di Open Access Journals. The 2015 edition of Journal Citation Reports [®] released by Reuters (ISI) cites the 2015 impact factor for <i>WJG</i> as 2.787 (5-year impact factor: 2.8 ing <i>WJG</i> as 38 among 78 journals in gastroenterology and hepatology (quartile in cate		as SciSearch [®]), Journal Citation Reports [®] , Index tral, Digital Object Identifier, and Directory of ournal Citation Reports [®] released by Thomson JG as 2.787 (5-year impact factor: 2.848), rank-			
FLYLEAF	I-IX Ec	litorial Board			
EDITORS FOR THIS ISSUE	Responsible	~ 1	le Science Editor: Ynan Qi Editorial Office Director: Jin-Lei Wang		
NAME OF JOURNAL World Journal of Gastroenterology ISSN ISSN 1007-9327 (print) ISSN 2219-2840 (online) LAUNCH DATE October 1, 1995 FREQUENCY Weekly EDITORS-IN-CHIEF Damian Garcia-Olmo, MD, PhD, Doctor, sor, Surgeon, Department of Surgery, Uni Autonoma de Madrid; Department of Gen gery, Fundacion Jimenez Diaz University F Madrid 28040, Spain Stephen C Strom, PhD, Professor, Depart Laboratory Medicine, Division of Patholog	Profes- rersidad tospital, r, Karo- Ba	A 90822, United States DITORIAL BOARD MEMBERS le ditorial board members resources online at http:// www.ignet.com/1007-9327/editorialboard.htm DITORIAL OFFICE -Lei Wang, Director -Mao Gong, Vice Director -Mao Gong, Vice Director ord/ Journal of Gastroenterology ishideng Publishing Group Inc 26 Regency Drive, easanton, CA 94588, USA lephone: +1-925-2238242 x: +1-925-2238243 mail: editorialoffice@wjgnet.com elp Desk: http://www.f6publishing.com/helpdesk p://www.wjgnet.com BLISHER ishideng Publishing Group Inc	http://www.wjgnet.com PUBLICATION DATE April 14, 2017 COPYRIGHT © 2017 Baishideng Publishing Group Inc. Articles pub- lished by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non- commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. SPECIAL STATEMENT All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opim- ions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated. INSTRUCTIONS TO AUTHORS		
linska Institutet, Stockholm 141-86, Sweden Andrzej S Tarnawski, MD, PhD, DSc Professor of Medicine, Chief Gastroentero Long Beach Health Care System, University fornia, Irvine, CA, 5901 E. Seventh Str., Lon	(Med), Ple (Med), Tel ogy, VA Fax of Cali- E-1	26 Regency Drive, 2asanton, CA 94588, USA lephone: +1-925-2238242 x:: +1-925-2238243 mail: bpgoffice@wjgnet.com 2lp Desk: http://www.f6publishing.com/helpdesk	Full instructions are available online at http://www. wjgnet.com/bpg/gerinfo/204 ONLINE SUBMISSION http://www.f6publishing.com		



Submit a Manuscript: http://www.f6publishing.com

DOI: 10.3748/wjg.v23.i14.2519

World J Gastroenterol 2017 April 14; 23(14): 2519-2526

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

ORIGINAL ARTICLE

Case Control Study

Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer

Kenichi Inaoka, Mitsuro Kanda, Hiroaki Uda, Yuri Tanaka, Chie Tanaka, Daisuke Kobayashi, Hideki Takami, Naoki Iwata, Masamichi Hayashi, Yukiko Niwa, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Kenta Murotani, Michitaka Fujiwara, Yasuhiro Kodera

Kenichi Inaoka, Mitsuro Kanda, Hiroaki Uda, Yuri Tanaka, Chie Tanaka, Daisuke Kobayashi, Hideki Takami, Naoki Iwata, Masamichi Hayashi, Yukiko Niwa, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Kenta Murotani, Michitaka Fujiwara, Yasuhiro Kodera, Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya 4668550, Japan

Kenta Murotani, Division of Biostatistics, Clinical Research Center, Aichi Medical University Hospital, Nagakute 4801195, Japan

Author contributions: Inaoka K wrote the manuscript; Kanda M and Kodera Y revised the text and contributed to the scientific analysis in the manuscript; Uda H, Tanaka Y, Tanaka C, Kobayashi D, Takami H, Iwata N, Hayashi M, Niwa Y, Yamada S, Fujii T, Sugimoto H, Fujiwara M contributed to data collection; Murotani K conducted the statistical analyses.

Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of the Nagoya University.

Informed consent statement: This study conforms to the ethical guidelines of the World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, and written informed consent for the use of clinical data were obtained from all patients.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Data sharing statement: No additional data are available for this study.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,

which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Mitsuro Kanda, MD, PhD, Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 4668550, Japan. m-kanda@med.nagoya-u.ac.jp Telephone: +81-52-7442249 Fax: +81-52-7442252

Received: December 25, 2016 Peer-review started: December 31, 2016 First decision: January 19, 2017 Revised: January 25, 2017 Accepted: March 20, 2017 Article in press: March 20, 2017 Published online: April 14, 2017

Abstract

AIM

To identify simple and sensitive markers for postoperative complications after gastrectomy, the predictive values were compared among candidate preoperative factors.

METHODS

Three-hundred and twelve patients with previously untreated clinical T2-4 gastric cancer who underwent a D2 standard gastrectomy (distal gastrectomy or total gastrectomy) were included in the analysis.



Correlations between 21 parameters that can be determined by preoperative routine blood tests and clinically relevant postoperative complications (grade II or higher according to the Clavien-Dindo classification) were evaluated. The optimal cutoff values and clinical significance of the selected markers were further evaluated by subgroup analyses according to age, body mass index, operative procedure and clinical disease stage.

RESULTS

Sixty-six patients (21.1%) experienced grade II or higher postoperative complications. The plateletlymphocyte ratio (PLR, total lymphocyte count/platelet count \times 100) exhibited the highest area under the curve value (0.639) for predicting postoperative complications among the 21 parameters, and the optimal cutoff value was determined to be 0.71 (sensitivity = 70%, specificity = 56%). In the univariate analysis, the odds ratio of a low PLR for the occurrence of postoperative complications was 2.94 (95%CI: 1.66-5.35, P < 0.001), and a multivariate binomial logistic analysis involving other potential risk factors identified a low PLR as an independent risk factor for postoperative complications (OR = 3.32, 95%CI: 1.82-6.25, P < 0.001). In subgroups classified according to age, body mass index, operative procedure and clinical disease stage, the low PLR group exhibited an increased incidence of postoperative complications.

CONCLUSION

The preoperative PLR is a simple and useful predictor of complications after curative gastrectomy in patients with clinical T2-4 gastric cancer.

Key words: Gastric cancer; Gastrectomy; Plateletlymphocyte ratio; Postoperative complication; Prediction

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The prediction of postoperative complications is important for providing appropriate perioperative management. In the present study, the predictive values for postoperative complications after gastrectomy with systemic lymphadenectomy for gastric cancer were compared among candidate preoperative factors to identify a simple and sensitive marker. Our results indicated that the preoperative platelet-lymphocyte ratio is a simple and useful predictor for complications after curative gastrectomy in patients with gastric cancer.

Inaoka K, Kanda M, Uda H, Tanaka Y, Tanaka C, Kobayashi D, Takami H, Iwata N, Hayashi M, Niwa Y, Yamada S, Fujii T, Sugimoto H, Murotani K, Fujiwara M, Kodera Y. Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer. *World J Gastroenterol* 2017; 23(14): 2519-2526 Available from: URL: http://www.wjgnet.com/1007-9327/full/

v23/i14/2519.htm DOI: http://dx.doi.org/10.3748/wjg.v23. i14.2519

INTRODUCTION

Gastrectomy with systemic lymphadenectomy is the mainstay of treatment for resectable gastric cancer (GC)^[1,2]. Despite advances in surgical techniques and devices, some patients who undergo the procedure experience clinically relevant postoperative complications, such as anastomotic leakage and intraabdominal abscess, leading to a protracted recovery period, delayed administration of adjuvant chemotherapy and impaired quality of life^[3,4]. Risk management is an increasingly important healthcare issue. Developing a prediction tool based exclusively on preoperatively determined factors to identify patients most at risk of postoperative complications enables surgeons to provide appropriate informed consent information and perioperative management, ultimately minimizing the medical cost burden^[5,6].

Increasing evidence indicates that multiple factors influence local infection control and the process of wound healing^[7]. Accordingly, numerous reports on predictive factors for postoperative complications, including inflammatory, immunological, nutritional, coagulation and organ functional indicators, have been published^[8-11]. However, limited information from cross-comparisons of these factors is available for patients who undergo a D2 gastrectomy for GC.

The aim of the present study was to compare the predictive values for postoperative complications after gastrectomy among candidate preoperative factors based on routinely obtained laboratory data. After the factor that demonstrated the highest predictive value was determined, the optimal cutoff value and its clinical significance were evaluated.

MATERIALS AND METHODS

Ethics

This study conforms to the ethical guidelines of the World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, and written informed consent for surgery and the use of clinical data were obtained from all patients as required by the Institutional Review Board of Nagoya University.

Patients, surgical procedure and perioperative treatment A total of 1194 patients underwent a gastrectomy for GC at the Department of Gastroenterological Surgery, Nagoya University between 1999 and 2016. We retrospectively analyzed the data of 312 patients according to the following inclusion criteria: no preoperative treatment; clinical T2-4 (advanced) GC according to the TNM Classification of Malignant

Table 1	Demographic and	preoperative clinical	characteristics
of 312 p	oatients		

Age, median (range) 66 (20-96) Sex	Variables	Number of patients
SexJabe233Male233Female79Diabetes mellitus79Absent273Present39Cardiac comorbidities95Absent217Present95Pulmonary comorbidities292Absent292Present200Preoperative symptoms21.9 ± 3.2Absent172Present140Preoperative body mass index, mean ± SD21.9 ± 3.2Tumor location8Upper third68Middle third120Lower third166Tumor size (mm)76 < 50 176 ≥ 50 136UICC cl factor71 $cT1$ 0 $cT2$ 150 $cT3$ 93 $cT4$ 67UICC cl factor73 $cN0$ 157 $cN1$ 93 $cN2$ 53 $cN3$ 9UICC clinical stage1IIA71IIB69IIIA55IIIB14		
Male233Female79Diabetes mellitus79Absent273Present20Cardiac comorbidities217Absent217Present95Pulmonary comorbidities20Absent292Present20Preoperative symptoms21.9 ± 3.2Absent172Present140Preoperative body mass index, mean ± SD21.9 ± 3.2Tumor location8Upper third68Middle third120Lower third116Tumor size (mm)76 < 50 136UICC cT factor76cT10cT2150cT395cT467UICC cN factor53cN193cN253cN39UICC clinical stage98IIA71IIB69IIIA55IIIB14		00 (20-90)
Female79Diabetes mellitus273Absent273Present39Cardiac comorbidities217Absent217Present292Pulmonary comorbidities292Absent292Present20Preoperative symptoms140Absent172Present140Preoperative body mass index, mean \pm SD21.9 \pm 3.2Tumor location8Upper third68Middle third120Lower third116Tumor size (mm)76 $<$ 50176 \geq 50136UICC cT factor150cT10cT2150cT395cT467UICC cN factor93cN393cN253cN394IIA71IB98IIA71IIB69IIIA55IIIB14		233
Diabetes mellitus273Absent273Present39Cardiac comorbidities217Absent217Present292Present202Present202Present201Preoperative symptoms140Absent172Present140Preoperative body mass index, mean \pm SD21.9 \pm 3.2Tumor location8Upper third68Middle third120Lower third116Tumor size (mm)136 $<$ 50136UICC cT factor150cT10cT2150cT339cT467UICC cN factor93cN0157cN193cN253cN39UICC clinical stage98II A69IIIA55III B69III A55III B14		
Absent273Present39Cardiac comorbidities217Absent217Present95Pulmonary comorbidities292Absent292Present200Preoperative symptoms172Absent172Present140Preoperative body mass index, mean \pm SD21.9 \pm 3.2Tumor location120Entire8Upper third68Middle third120Lower third116Tumor size (mm)76< 50		
Present39Cardiac comorbidities217Absent217Present95Pulmonary comorbidities292Absent292Present20Preoperative symptoms172Absent172Present140Preoperative body mass index, mean ± SD21.9 ± 3.2Tumor location8Upper third68Middle third100Lower third116Tumor size (mm)6< 50		273
Cardia comorbidities217Absent217Present95Pulmonary comorbidities292Absent292Present20Preoperative symptoms172Absent172Present140Preoperative body mass index, mean \pm SD21.9 \pm 3.2Tumor location8Entire8Upper third68Middle third120Lower third116Tumor size (mm)76 $<$ 50176 \geq 50136UICC cT factor150cT10cT2150cT395cT467UICC cN factor93cN253cN39UICC clinical stage11I B98II A71I B69II A55II B14		
Absent217Present95Pulmonary comorbidities292Present20Preoperative symptoms172Absent172Present140Preoperative body mass index, mean \pm SD21.9 \pm 3.2Tumor location8Entire8Upper third68Middle third120Lower third116Tumor size (mm)176< 50		
Pulmonary comorbidities292Absent292Present20Preoperative symptoms172Absent172Present140Preoperative body mass index, mean \pm SD21.9 \pm 3.2Tumor location8Upper third68Middle third120Lower third116Tumor size (mm)176 \leq 50176 \geq 50136UICC cT factor0cT10cT2150cT395cT467UICC cN factor157cN193cN253cN39UICC clinical stage9IIA71IIB69IIIA55IIIB14		217
Pulmonary comorbidities292Absent292Present20Preoperative symptoms172Absent172Present140Preoperative body mass index, mean \pm SD21.9 \pm 3.2Tumor location8Upper third68Middle third120Lower third116Tumor size (mm)176 \leq 50176 \geq 50136UICC cT factor0cT10cT2150cT395cT467UICC cN factor157cN193cN253cN39UICC clinical stage9IIA71IIB69IIIA55IIIB14	Present	95
Absent292Present20Preoperative symptoms172Absent172Present140Preoperative body mass index, mean \pm SD21.9 \pm 3.2Tumor location8Entire8Upper third68Middle third120Lower third116Tumor size (mm)76< 50		
Preoperative symptoms172Absent172Present140Preoperative body mass index, mean \pm SD 21.9 ± 3.2 Tumor location 110 Entire8Upper third68Middle third120Lower third116Tumor size (mm) 176 ≤ 50 176 ≥ 50 136UICC cT factor 0 cT1 0 cT2150cT395cT467UICC cN factor 93 cN1 93 cN2 53 cN3 9 UICC clinical stage $11A$ I B 98 II A 71 I B 69 IIIA 55 II B 14	-	292
Absent172Present140Preoperative body mass index, mean \pm SD 21.9 ± 3.2 Tumor location 21.9 ± 3.2 Entire8Upper third68Middle third120Lower third116Tumor size (mm) < 50 < 50 176 ≥ 50 136UICC cT factor 0 cT1 0 cT2150cT395cT467UICC cN factor 0 cN193cN253cN39UICC clinical stage 71 I B98II A71I B69IIIA55II B14	Present	20
Absent172Present140Preoperative body mass index, mean \pm SD 21.9 ± 3.2 Tumor location 21.9 ± 3.2 Entire8Upper third68Middle third120Lower third116Tumor size (mm) < 50 < 50 176 ≥ 50 136UICC cT factor 0 cT1 0 cT2150cT395cT467UICC cN factor 0 cN193cN253cN39UICC clinical stage 71 I B98II A71I B69IIIA55II B14	Preoperative symptoms	
Preoperative body mass index, mean \pm SD 21.9 ± 3.2 Tumor location 8 Entire8Upper third68Middle third120Lower third116Tumor size (mm) < 50 < 50 176 \geq 50136UICC cT factor 0 cT10cT2150cT395cT467UICC cN factor 93 cN193cN253cN39UICC clinical stage $11A$ I B98II A71I B69IIIA55II B14		172
Tumor locationEntire8Upper third68Middle third120Lower third116Tumor size (mm) < 50 < 50 176 ≥ 50 136UICC cT factor < 70 cT10cT2150cT395cT467UICC cN factor < 157 cN193cN253cN39UICC clinical stage < 71 I B98II A71I B69IIIA55II B14	Present	140
Entire 8 Upper third 68 Middle third 120 Lower third 116 Tumor size (mm) - < 50	Preoperative body mass index, mean ± SD	21.9 ± 3.2
Upper third 68 Middle third 120 Lower third 116 Tumor size (mm) 1 < 50	Tumor location	
Middle third 120 Lower third 116 Tumor size (mm) 176 ≤ 50 176 ≥ 50 136 UICC cT factor 0 cT1 0 cT2 150 cT3 95 cT4 67 UICC cN factor 157 cN1 93 cN2 53 cN3 9 UICC clinical stage 1 I B 98 II A 71 I B 69 III A 55 II B 14	Entire	8
Lower third 116 Tumor size (mm) 176 < 50 136 UICC cT factor 0 cT1 0 cT2 150 cT3 95 cT4 67 UICC cN factor 157 cN1 93 cN2 53 cN3 9 UICC clinical stage 9 I B 98 II A 71 I B 69 III A 55 III B 14	Upper third	68
Tumor size (mm) < 50	Middle third	120
< 50	Lower third	116
≥ 50136UICC cT factorcT10cT2150cT395cT467UICC cN factor157cN193cN253cN39UICC clinical stage9I B98II A71I B69II A55II B14	Tumor size (mm)	
UICC cT factor cT1 0 cT2 150 cT3 95 cT4 67 UICC cN factor 157 cN1 93 cN2 53 cN3 9 UICC clinical stage 11 I B 98 II A 71 I B 69 III A 55 III B 14	< 50	176
cT1 0 cT2 150 cT3 95 cT4 67 UICC cN factor 157 cN1 93 cN2 53 cN3 9 UICC clinical stage 98 II A 71 II B 69 III A 55 III B 14	≥ 50	136
cT2 150 cT3 95 cT4 67 UICC cN factor 157 cN1 93 cN2 53 cN3 9 UICC clinical stage 9 I B 98 II A 71 I B 69 II A 55 II B 14	UICC cT factor	
cT3 95 cT4 67 UICC cN factor 157 cN0 157 cN1 93 cN2 53 cN3 9 UICC clinical stage 9 I B 98 II A 71 I B 69 II A 55 II B 14	cT1	0
cT4 67 UICC cN factor 157 cN0 157 cN1 93 cN2 53 cN3 9 UICC clinical stage 9 I B 98 II A 71 I B 69 II A 55 II B 14	cT2	150
UICC cN factor cN0 157 cN1 93 cN2 53 cN3 9 UICC clinical stage I B 98 II A 71 II B 69 III A 55 III B 14	cT3	95
cN0 157 cN1 93 cN2 53 cN3 9 UICC clinical stage 71 I B 98 II A 71 II B 69 III A 55 III B 14	cT4	67
cN1 93 cN2 53 cN3 9 UICC clinical stage 71 II A 71 II B 69 III A 55 III B 14	UICC cN factor	
cN2 53 cN3 9 UICC clinical stage 98 II A 71 II B 69 III A 55 III B 14	cN0	157
cN3 9 UICC clinical stage 9 I B 98 II A 71 II B 69 III A 55 III B 14		
UICC clinical stage I B 98 II A 71 II B 69 III A 55 III B 14	cN2	53
I B 98 II A 71 II B 69 III A 55 III B 14	cN3	9
Π A 71 Π B 69 Π A 55 Π B 14		
Ⅱ B 69 Ⅲ A 55 Ⅲ B 14		
ⅢA 55 ⅢB 14		
ШВ 14		
ШС 5		
	ШС	5

UICC: Union for International Cancer Control.

Tumours, 7th Edition^[12]; D2 gastrectomy (distal gastrectomy or total gastrectomy) performed according to the Japanese Gastric Cancer Treatment Guidelines^[13]; no combined resection of other organs except for the spleen and gallbladder; R0 gastrectomy performed and sufficient data for analysis. The choice of the reconstruction method was at the surgeon's discretion. A first-generation cephem-based antibiotic was administered immediately before surgery and every 3 h during surgery. Oral intake was routinely started on postoperative day 1 if no obvious problems were found. Percutaneous drainage or the replacement of drainage tubes was performed when signs of inadequate drainage were noted by computed tomography or ultrasound scans. Clinically relevant postoperative complications were defined as those of grade II or higher according

to the Clavien-Dindo classification^[14].

Study parameters

Blood tests were routinely performed two days before surgery. Data were collected retrospectively from the medical records focusing on five categories: blood cell count, coagulation, nutrition, renal function and inflammation. The parameters investigated as candidate predictive factors for postoperative complications, which can be rapidly measured in every hospital, included the following: white blood cell count, neutrophil count, total lymphocyte count (TLC), hemoglobin concentration, platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, total protein, albumin, cholinesterase, total cholesterol, urea nitrogen, creatinine and C-reactive protein (CRP). In addition, some simple indices were employed as candidate indicators: neutrophil-lymphocyte ratio (NLR = neutrophil count/TLC), platelet-neutrophil ratio (PNR = neutrophil count/platelet count \times 100), plateletlymphocyte ratio (PLR = TLC/platelet count \times 100), Onodera's PNI (PNI = $10 \times \text{albumin g/dL} + 0.005 \times$ TLC/mm³), Glasgow prognostic score (GPS) and the modified GPS^[7,8,15].

Subgroup analyses

Subgroup analyses according to age, body mass index (BMI), operative procedure and clinical disease stage were performed to evaluate the correlations between the selected predictive factors and the incidence of clinically relevant postoperative complications.

Statistical analysis

A receiver operating characteristic (ROC) curve analysis was employed to calculate the area under the curve (AUC) and the sensitivity and specificity of the indicated variables to predict postoperative complications. The optimal cutoff value was determined using the Youden index^[16]. The qualitative χ^2 test and quantitative Mann-Whitney test were used to compare the two groups. Multivariable analysis was performed to identify independent risk factors for postoperative complications using binomial logistic analysis, and variables with a value of P < 0.05 were included as covariates in the final model. All statistical analyses were performed using JMP 10 software (SAS Institute Inc., NC, United States). A statistically significant difference was indicated by a *P*-value < 0.05.

RESULTS

Patient characteristics

The demographic and preoperative characteristics of the 312 patients are presented in Table 1. The median age was 66 years, and the male-to female ratio was 233:79. With respect to preoperative staging, 98, 71, 69, 55, 14 and 5 patients were classified as clinical TNM stages I B, II A, II B, III A, III B and III C, respectively.

Inaoka K et al. PLR predicts complications after gastrectomy




Figure 1 Comparison of the predictive value of potential indicators. A: Area under the curve values of potential predictors; B: Predictive values of lymphocyte count, platelet count and PLR for postoperative complications evaluated by receiver operating characteristic curve analysis. PLR: Platelet-lymphocyte ratio.

Comparison of predictive values among the candidate parameters

In total, 66 patients (21.1%) had grade II or higher postoperative complications. In terms of the types of complications, the cumulative numbers of patients who experienced anastomotic leakage, leakage of pancreatic fluids, intraabdominal abscess and bowel obstruction were 20 (6.4%), 12 (3.8%), 19 (6.1%) and 6 (1.9%), respectively. When the AUC value, which indicates the power to predict postoperative complications, of the 21 parameters was analyzed, the PLR demonstrated the highest AUC value (0.639) (Figure 1A). This value was greater than the values of the PLR components TLC (AUC 0.563) and platelet count (AUC 0.615) (Figure 1B). The optimal cutoff value for predicting complications using the PLR was set at 0.71 (sensitivity = 70%, specificity = 56%) (Figure 1B). The AUC values of NLR, PNR, PNI and GPS were 0.566 (cutoff = 3.06), 0.574 (cutoff = 1.36), 0.608 (cutoff = 47.0) and 0.582 (cutoff = 1), respectively (Figure 1A).

Predictive value of the PLR

The median PLR was 0.71 (range 0.23-3.97), which is identical to the proposed cutoff. Using the cutoff indicated by the ROC curve analysis, we further evaluated the clinical significance of the PLR. Patients were categorized into two groups, the high (n = 158) and low (n = 154) PLR groups, using a PLR cutoff of 0.71. Compared to the high PLR group, patients in the low PLR group were associated with increased prevalence of pulmonary comorbidities, larger macroscopic tumor size and more frequent postoperative complications (Table 2). However, no significant differences were observed between the two groups regarding age, sex, preoperative BMI, clinical stage, type of gastrectomy, operative time, intraoperative blood loss and number of dissected lymph nodes (Table 2). In the univariate analysis, the odds ratio of a low PLR for postoperative complications was 2.94 (95%CI: 1.66-5.35, P < 0.001; Table 3). We next conducted a multivariable binomial logistic analysis involving other potential risk factors determined before surgery and found that a low PLR was an independent risk factor for postoperative complications (odds ratio 3.32, 95%CI: 1.82-6.25, P < 0.001) along with male sex and total gastrectomy (Table 3). With respect to the types of complications, the low PLR group exhibited an increased prevalence of anastomotic leakage, leakage of pancreatic fluids, intraabdominal abscess and bowel obstruction compared to the high PLR group. However, the differences were not statistically significant (Figure 2). By contrast, the incidence of cardiopulmonary dysfunction was comparable between the two groups.

Subgroup analyses

To further evaluate the clinical effect of the preoperative PLR on the postoperative course, subgroup analyses were conducted according to age (< 65 years or \geq 65 years), preoperative BMI (< 22 or \geq 22),



WJG www.wjgnet.com

the preoperative platelet-lyn	nphocyte ratio)	
Variables	PLR < 0.71 (<i>n</i> = 154)	$PLR \ge 0.71$ (<i>n</i> = 158)	<i>P</i> value
Age, median (range)	66 (20-86)	66 (34-96)	0.661
Sex			0.434
Male	112	121	
Female	42	37	0.070
Diabetes mellitus Absent	140	133	0.070
Present	140	25	
Cardiac comorbidities	14	25	0.785
Absent	106	111	000
Present	48	47	
Pulmonary comorbidities			0.021
Absent	149	143	
Present	5	15	
Preoperative symptoms			0.838
Absent	84	88	
Present	70	70	
Preoperative body mass index, mean ± SD	21.6 ± 3.3	22.2 ± 3.1	0.102
Tumor location			0.673
Entire	3	5	0.075
Upper third	32	36	
Middle third	57	63	
Lower third	62	54	
Tumor size (mm)			0.043
< 50	78	98	
≥ 50	76	60	
UICC cT factor			0.502
cT1	0	0	
cT2	69	81	
cT3	49	46	
cT4 UICC cN factor	36	31	0 622
cN0	75	82	0.633
cN1	51	42	
cN2	24	29	
cN3	4	5	
UICC clinical stage			0.823
IB	45	53	
ΠА	37	34	
ШΒ	32	37	
ША	31	24	
ШВ та	7	7	
	2	3	0.440
Operative procedure	52	57	0.669
Total gastrectomy	52 102	57 101	
Distal gastrectomy	102	101	0.191
Splenectomy Absent	128	122	0.191
Present	26	36	
Dissected lymph nodes,	37.6 ± 15.8	38.7 ± 18.0	0.823
mean ± SD			
Operative time (min),	233 ± 56	238 ± 74	0.720
mean ± SD			
Estimated blood loss (mL),	237 (1-2350)	245 (8-4267)	0.491
median (range)			
Postoperative complications			< 0.001
Absent	108	138	
Present	46	20	

 Table 2 Comparison between two subgroups according to

ive platelet-lymphocyte

PLR: Platelet-lymphocyte ratio; UICC: Union for International Cancer Control.

operative procedure (distal or total gastrectomy) and clinical disease stage. The low PLR group exhibited an

increased incidence of postoperative complications for all subgroup analyses (Figure 3).

DISCUSSION

The PLR, a combination of circulating platelet and lymphocyte counts, is a representative index of systemic inflammation and immune status^[9,17]. Accordingly, a decreased PLR value indicate both systemic inflammation and compromised immune reaction. Although preoperative systemic inflammation has been reported as an underlying characteristic that predisposes the host to postoperative infection, only limited evidence is available^[18]. In this study, a significant relationship between the preoperative PLR and postoperative complications was demonstrated. The PLR exhibited the highest AUC value for the incidence of postoperative complications among the candidate parameters obtained from routine preoperative blood tests. A low preoperative PLR was identified as an independent risk factor for postoperative complications in the multivariable analysis. Moreover, a low preoperative PLR was associated with an increased incidence of postoperative complications independent of age, BMI, operative procedure and disease stage, indicating that the preoperative PLR is applicable to various clinical settings.

The PLR can be determined in every hospital and is the subject of interest as a marker of systemic inflammation in various clinical circumstances. Several reports indicate that the PLR can serve as a prognostic factor for digestive malignancies^[9,18]. Accumulating evidence indicates that a systemic inflammatory response could play an important role in the development and progression of cancer. Inflammation is closely related to different stages of tumor development, including initiation, invasion, metastasis, immune surveillance and responses to therapy^[7,8,10,19,20]. However, the clinical impact of the preoperative PLR on postoperative short-term outcomes, particularly in patients undergoing a gastrectomy, remains unclear. Our results suggested that surgeons can provide precise informed consent information and identify high-risk patients to tailor perioperative care as an attempt to ultimately improve postoperative short-term outcomes for GC patients undergoing a gastrectomy using this prediction tool. Recently, preoperative risk calculation systems based on large-scale integrated databases, such as the Surgical Risk Preoperative Assessment System (SURPAS) and the Physiologic and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) model, have been widely used in clinical practice^[5,21]. Our data suggest that the PLR could at least become a potential constituent of integrated scoring systems for surgical risk assessment.

The association between a decreased PLR and the development of postoperative infectious complication

Table 3 Predictive factors for grade 2 or higher complications according to the Clavien-Dindo system: Univariate and multivariable analyses

Variables	Univariate			Multivariable		
	Odds ratio	95%CI	P value	Odds ratio	95%CI	P value
Age (≥ 65 yr)	1.26	0.73-2.23	0.410			
Gender (male)	4.22	1.88-11.3	< 0.001	4.17	1.78-11.5	< 0.001
Preoperative symptoms	0.95	0.55-1.64	0.864			
Diabetes mellitus	1.14	0.49-2.45	0.755			
Cardiac comorbidities	1.81	1.02-3.18	0.041	1.55	0.83-2.87	0.166
Pulmonary comorbidities	1.26	0.40-3.40	0.669			
Body mass index (≥ 22)	1.62	0.94-2.81	0.084			
Preoperative PLR (< 0.71)	2.94	1.66-5.35	< 0.001	3.32	1.82-6.25	< 0.001
Tumor location (lower third)	0.62	0.34-1.11	0.107			
Macroscopic tumor size (> 50 mm)	1.19	0.69-2.05	0.534			
UICC cT (cT4)	1.30	0.67-2.69	0.457			
UICC cN (cN1-3)	1.75	1.01-3.08	0.045	1.69	0.93-3.08	0.083
Operative procedure (total gastrectomy)	2.42	1.39-4.23	0.002	2.43	1.35-4.43	< 0.001

Analyses were performed using binomial logistic analysis. PLR: Platelet-lymphocyte ratio; UICC: Union for International Cancer Control.





Figure 2 Comparison of the prevalence of each complication type between the high and low platelet-lymphocyte ratio groups.

is likely complex and remains unclear. One plausible explanation is that a decreased PLR may reflect four disadvantages for the postoperative course including an inflammatory status, immune disorders, malnutrition and a tendency for micro-vessel thrombosis^[10,18]. A decreased PLR collectively reflects a reduced TLC (compromised cell-mediated immunity and malnutrition) and an increased platelet count (inflammation and high thromphophilic diathesis). Lymphocytopenia is associated with malnutrition and cellular immunosuppression^[22-24]. A pro-inflammatory status leads to compromised cell-mediated immunity and an impaired T-lymphocytic response via cytokines^[25]. The ability of myeloid cells to synthesize pro-inflammatory and anti-inflammatory mediators is affected by their previous state^[10,18]. Malnutrition is a major cause of delayed wound healing^[11,15]. A decreased lymphocyte-mediated antibacterial immune reaction may weaken the lymphocyte-mediated antibacterial cellular immune response and contribute to increasing bacterial invasion and $growth^{[10,18]}$. The platelet count is recognized as a marker of a systemic inflammatory response and potential micro-vessel thrombosis^[7,9,17]. Formation of micro-vessel thrombosis

inhibits wound healing via the deterioration of blood circulation in tissues. Eventually, the crosstalk of these complex factors increases the incidence of postoperative complications. In addition, our findings raised two questions. First, why is the PLR was more sensitive than the other indices, such as the PNI and GPS? We hypothesize that the PLR is indicative of four elements, including inflammatory status, immune disorders, malnutrition and a tendency for microvessel thrombosis, and therefore it was more closely associated with postoperative complications than other indices. Another question is whether preoperative modification of the PLR by anti-inflammatory treatment and nutritional support reduces the adverse effects on the postoperative clinical course. Further investigations are needed to answer these questions.

The current study also had several limitations that should not be ignored. This was a retrospective study of a limited number of patients from a single institute. Thus, our findings require validation by further largescale prospective studies. To further evaluate the association of the PLR with the host inflammatory and nutritional status, information on levels of cytokines and rapid turnover proteins is required.



Inaoka K et al. PLR predicts complications after gastrectomy

Figure 3 Subgroup analyses. The morbidity rates were compared between the high and low PLR groups according to age (A), body mass index (B), operative procedure (C) and clinical disease stage (D). Comparison of predictive value of potential indicators. PLR: Platelet-lymphocyte ratio.

Taken together, the results indicate that the preoperative PLR is a simple and useful predictor of postoperative complications in patients who undergo a gastrectomy with systemic lymphadenectomy for GC. In the future, the development of an integrated risk stratification system using the PLR may facilitate physicians' decision-making and contribute to the informed consent process before a gastrectomy.

COMMENTS

Background

Patients undergoing a gastrectomy with systemic lymphadenectomy for gastric cancer occasionally experience clinically relevant postoperative complications. Development of a prediction tool based on preoperatively determined factors would be helpful to identify individuals at risk of postoperative complications for whom precise informed consent and tailored perioperative management could be provided.

Research frontiers

Platelet-lymphocyte ratio (PLR) showed the highest predictive value for postoperative complications among the 21 parameters. It was found to be an independent risk factor in a multivariate binomial logistic analysis.

Innovations and breakthroughs

The authors found that PLR served as a predictor of postoperative complications in all subgroups classified according to age, body mass index, operative procedure and clinical disease stage.

Applications

PLR is a simple and useful predictor of postoperative complications in patients who undergo a gastrectomy with systemic lymphadenectomy for gastric cancer. It may facilitate physicians' decision-making and contribute to the informed consent process before a gastrectomy.

Terminology

PLR is a platelet-lymphocyte ratio (total lymphocyte count/platelet count × 100) and is a representative index of systemic inflammation and immune status.

Peer-review

This is an interesting, single center retrospective study on clinical utility of preoperative predictors of postoperative complications for clinical T2-4 gastric cancer. The authors made a high quality statistical analysis and found a new statistical, easy, reproducible and overall available index, the PLR, to predict the postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer.

REFERENCES

- Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. *Lancet* 2016; **388**: 2654-2664 [PMID: 27156933 DOI: 10.1016/s0140-6736(16)30354-3]
- 2 Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, Murotani K, Fujiwara M, Kodera Y. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. *Gastric Cancer* 2016; **19**: 255-263 [PMID: 25563579 DOI: 10.1007/s10120-014-0456-x]

Inaoka K et al. PLR predicts complications after gastrectomy

- 3 Kurita N, Miyata H, Gotoh M, Shimada M, Imura S, Kimura W, Tomita N, Baba H, Kitagawa Y, Sugihara K, Mori M. Risk Model for Distal Gastrectomy When Treating Gastric Cancer on the Basis of Data From 33,917 Japanese Patients Collected Using a Nationwide Web-based Data Entry System. *Ann Surg* 2015; 262: 295-303 [PMID: 25719804 DOI: 10.1097/sla.000000000001127]
- 4 Kanda M, Tanaka C, Kobayashi D, Mizuno A, Tanaka Y, Takami H, Iwata N, Hayashi M, Niwa Y, Yamada S, Fujii T, Sugimoto H, Murotani K, Fujiwara M, Kodera Y. Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer. *Ann Surg Oncol* 2017; 24: 502-509 [PMID: 27600621 DOI: 10.1245/s10434-016-5544-1]
- 5 Meguid RA, Bronsert MR, Juarez-Colunga E, Hammermeister KE, Henderson WG. Surgical Risk Preoperative Assessment System (SURPAS): III. Accurate Preoperative Prediction of 8 Adverse Outcomes Using 8 Predictor Variables. *Ann Surg* 2016; 264: 23-31 [PMID: 26928465 DOI: 10.1097/sla.000000000001678]
- 6 Tanaka Y, Kanda M, Tanaka C, Kobayashi D, Mizuno A, Iwata N, Hayashi M, Niwa Y, Takami H, Yamada S, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2-4 gastric cancer. *Gastric Cancer* 2016; Epub ahead of print [PMID: 27734274 DOI: 10.1007/s10120-016-0657-6]
- 7 Neal CP, Mann CD, Garcea G, Briggs CD, Dennison AR, Berry DP. Preoperative systemic inflammation and infectious complications after resection of colorectal liver metastases. *Arch Surg* 2011; 146: 471-478 [PMID: 21502458 DOI: 10.1001/ archsurg.2011.50]
- 8 Moyes LH, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. *Br J Cancer* 2009; 100: 1236-1239 [PMID: 19319134 DOI: 10.1038/sj.bjc.6604997]
- 9 Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, Wang T, Zhu W, Liu P. Prognostic value of PLR in various cancers: a meta-analysis. *PLoS One* 2014; 9: e101119 [PMID: 24968121 DOI: 10.1371/ journal.pone.0101119]
- 10 Mohri Y, Tanaka K, Toiyama Y, Ohi M, Yasuda H, Inoue Y, Kusunoki M. Impact of Preoperative Neutrophil to Lymphocyte Ratio and Postoperative Infectious Complications on Survival After Curative Gastrectomy for Gastric Cancer: A Single Institutional Cohort Study. *Medicine* (Baltimore) 2016; **95**: e3125 [PMID: 26986164 DOI: 10.1097/md.0000000003125]
- 11 Kanda M, Mizuno A, Tanaka C, Kobayashi D, Fujiwara M, Iwata N, Hayashi M, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Takami H, Niwa Y, Murotani K, Kodera Y. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. *Medicine* (Baltimore) 2016; **95**: e3781 [PMID: 27310954 DOI: 10.1097/md.00000000003781]
- 12 Sobin LH, Gospodarowicz MK, C W. International Union Against Cancer, TNM Classification of Malignant Tumors. Seventh Edition. New York: Wiley-Blackwell, 2009
- Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017; 20: 1-19 [PMID: 27342689 DOI: 10.1007/s10120-016-0622-4]
- 14 Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 2009; **250**: 187-196 [PMID: 19638912 DOI: 10.1097/SLA.0b013e3181b13ca2]

- 15 Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 2011; 98: 268-274 [PMID: 20960457 DOI: 10.1002/bjs.7305]
- 16 Kanda M, Murotani K, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis. *Surgery* 2015; **158**: 1573-1580 [PMID: 26120068 DOI: 10.1016/ j.surg.2015.05.017]
- 17 Kim EY, Lee JW, Yoo HM, Park CH, Song KY. The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer? *Ann Surg Oncol* 2015; 22: 4363-4370 [PMID: 25805235 DOI: 10.1245/s10434-015-4518-z]
- 18 Pang W, Lou N, Jin C, Hu C, Arvine C, Zhu G, Shen X. Combination of preoperative platelet/lymphocyte and neutrophil/ lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer. *Eur J Gastroenterol Hepatol* 2016; 28: 493-502 [PMID: 26854795 DOI: 10.1097/ meg.000000000000563]
- 19 Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K, Röcken M. T-helper-1-cell cytokines drive cancer into senescence. *Nature* 2013; **494**: 361-365 [PMID: 23376950 DOI: 10.1038/ nature11824]
- 20 Kanda M, Mizuno A, Fujii T, Shimoyama Y, Yamada S, Tanaka C, Kobayashi D, Koike M, Iwata N, Niwa Y, Hayashi M, Takami H, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Tumor Infiltrative Pattern Predicts Sites of Recurrence After Curative Gastrectomy for Stages 2 and 3 Gastric Cancer. *Ann Surg Oncol* 2016; 23: 1934-1940 [PMID: 26847679 DOI: 10.1245/s10434-016-5102-x]
- 21 Chen T, Wang H, Wang H, Song Y, Li X, Wang J. POSSUM and P-POSSUM as predictors of postoperative morbidity and mortality in patients undergoing hepato-biliary-pancreatic surgery: a metaanalysis. *Ann Surg Oncol* 2013; 20: 2501-2510 [PMID: 23435569 DOI: 10.1245/s10434-013-2893-x]
- 22 Watanabe M, Iwatsuki M, Iwagani S, Ishimoto T, Baba Y, Baba H. Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. *World J Surg* 2012; 36: 1632-1639 [PMID: 22407085 DOI: 10.1007/s00268-012-1526-z]
- 23 Song GM, Tian X, Liang H, Yi LJ, Zhou JG, Zeng Z, Shuai T, Ou YX, Zhang L, Wang Y. Role of Enteral Immunonutrition in Patients Undergoing Surgery for Gastric Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicine* (Baltimore) 2015; 94: e1311 [PMID: 26252314 DOI: 10.1097/md.000000000001311]
- 24 Wang F, Hou MX, Wu XL, Bao LD, Dong PD. Impact of enteral nutrition on postoperative immune function and nutritional status. *Genet Mol Res* 2015; 14: 6065-6072 [PMID: 26125807 DOI: 10.4238/2015.June.8.4]
- 25 Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. *World J Surg* 2015; **39**: 1501-1509 [PMID: 25670038 DOI: 10.1007/s00268-015-2982-z]

P- Reviewer: Eleftheriadis NP, Namikawa T L- Editor: A S- Editor: Gong ZM E- Editor: Wang CH







Published by Baishideng Publishing Group Inc

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com





© 2017 Baishideng Publishing Group Inc. All rights reserved.